All Outputs (6)

Quantum Dot Imaging Agents: Haematopoietic Cell Interactions and Biocompatibility (2024)
Journal Article
Naylor-Adamson, L., Price, T. W., Booth, Z., Stasiuk, G. J., & Calaminus, S. D. (2024). Quantum Dot Imaging Agents: Haematopoietic Cell Interactions and Biocompatibility. Cells, 13(4), Article 354. https://doi.org/10.3390/cells13040354

Quantum dots (QDs) are semi-conducting nanoparticles that have been developed for a range of biological and non-biological functions. They can be tuned to multiple different emission wavelengths and can have significant benefits over other fluorescen... Read More about Quantum Dot Imaging Agents: Haematopoietic Cell Interactions and Biocompatibility.

Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets (2023)
Journal Article
Gil, H. M., Booth, Z., Price, T. W., Lee, J., Naylor‐Adamson, L., Avery, M., …Stasiuk, G. J. (in press). Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets. Small, Article 2304881. https://doi.org/10.1002/smll.202304881

InP/ZnS quantum dots (QDs) have received a large focus in recent years as a safer alternative to heavy metal-based QDs. Given their intrinsic fluorescent imaging capabilities, these QDs can be potentially relevant for in vivo platelet imaging. The In... Read More about Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets.

Platelet zinc status regulates prostaglandin-induced signaling, altering thrombus formation (2023)
Journal Article
Coupland, C. A., Naylor-Adamson, L., Booth, Z., Price, T. W., Gil, H. M., Firth, G., …Calaminus, S. D. (2023). Platelet zinc status regulates prostaglandin-induced signaling, altering thrombus formation. Journal of thrombosis and haemostasis : JTH, 21(9), 2545-2558. https://doi.org/10.1016/j.jtha.2023.05.008

Background: Approximately 17.3% of the global population exhibits an element of zinc (Zn2+) deficiency. One symptom of Zn2+ deficiency is increased bleeding through impaired hemostasis. Platelets are crucial to hemostasis and are inhibited by endothe... Read More about Platelet zinc status regulates prostaglandin-induced signaling, altering thrombus formation.

Practical considerations of dissolved oxygen levels for platelet function under hypoxia (2021)
Journal Article
Kusanto, B., Gordon, A., Naylor-Adamson, L., Atkinson, L., Coupland, C., Booth, Z., …Arman, M. (2021). Practical considerations of dissolved oxygen levels for platelet function under hypoxia. International Journal of Molecular Sciences, 22(24), Article 13223. https://doi.org/10.3390/ijms222413223

Investigating human platelet function in low-oxygen environments is important in multiple settings, including hypobaric hypoxia (e.g., high altitude), sea level hypoxia-related disease, and thrombus stability. These studies often involve drawing bloo... Read More about Practical considerations of dissolved oxygen levels for platelet function under hypoxia.

Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia (2021)
Journal Article
Naylor-Adamson, L., Chacko, A., Booth, Z., Caserta, S., Jarvis, J., Khan, S., …Arman, M. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia. Frontiers in immunology, 12, Article 766272. https://doi.org/10.3389/fimmu.2021.766272

Bacterial infections are a major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), and infection risk increases in patients treated with the Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib. Btk and related kinases (like Tec)... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia.

Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia (2021)
Thesis
Naylor-Adamson, L. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4224129

Ibrutinib is highly effective in the treatment of chronic lymphocytic leukaemia (CLL), disrupting B cell receptor signalling through the inhibition of Bruton’s tyrosine kinase (Btk). However, ibrutinib has off-target effects, inhibiting platelet aggr... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia.